1. Generics Bulletin
  2. >>Policy & Regulation

AAM Blasts Build Back Better But Bernstein Offers Balance

Discounted Drugs Could Disincentivize US Biosimilar Competition, Says AAM

 
• By Chloe Kent

Biosimilars could be affected significantly by Build Back Better’s drug price negotiations provision, but industry associations and analysts differ on just how much.

Joe Biden stands in front of a Build Back Better poster
Build Back Better's proposed price controls could have a negative affect on the biosimilars industry • Source: Alamy

The US Association for Accessible Medicines has continued to criticize the Biden administration’s proposed Build Back Better Act due to the negative affect it could have on the biosimilars industry. The organization maintains that, as it currently stands, allowing free biosimilar competition will achieve more savings for patients than Build Back Better’s price negotiation model.

Under the proposal, the Department of Health and Human Services would have the authority to negotiate drug prices with manufacturers,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

More from Generics Bulletin

Celltrion Reinforces Commitment To UK Biosimilars Market With New HQ

 
• By Dave Wallace

Celltrion has reinforced its commitment to the UK by opening a new central operations hub in Uxbridge, while acknowledging that “major questions over the attractiveness of the market” need to be addressed to encourage development and ensure a sustainable environment for UK biosimilars.

‘Prices Can Remain Contaminated Indefinitely’: Advanz Brushed Aside On UK Liothyronine Appeal

 
• By Dean Rudge

England’s Court of Appeal has upheld a Competition Appeal Tribunal’s 2023 finding that Advanz and its former owner Cinven abused their dominant position in the UK market for liothyronine tablets by charging prices that were many orders of magnitude higher than the benchmark for fair pricing.

Tevogen Will House Generics Unit In Much-Expanded New Headquarters

 
• By Dean Rudge

Tevogen is looking to accelerate its growth with a major expansion of its headquarters in Warren, New Jersey, more than doubling its footprint to centralize research and development, regulatory, and corporate functions. The new facility will support the company’s evolving initiatives.